Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 194


An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.

Bozek K, Eckhardt M, Sierra S, Anders M, Kaiser R, Kräusslich HG, Müller B, Lengauer T.

Retrovirology. 2012 Jul 25;9:60. doi: 10.1186/1742-4690-9-60.


Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry.

Westby M, Smith-Burchnell C, Mori J, Lewis M, Mosley M, Stockdale M, Dorr P, Ciaramella G, Perros M.

J Virol. 2007 Mar;81(5):2359-71. Epub 2006 Dec 20.


Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.

Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.

AIDS. 2008 Jul 31;22(12):1425-31. doi: 10.1097/QAD.0b013e32830184ba.


Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.

Panos G, Watson DC.

Crit Rev Microbiol. 2015;41(4):473-87. doi: 10.3109/1040841X.2013.867829. Epub 2014 Mar 17. Review.


Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.

Hunt JS, Romanelli F.

Pharmacotherapy. 2009 Mar;29(3):295-304. doi: 10.1592/phco.29.3.295. Review.


Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7.


HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.

Moncunill G, Armand-Ugón M, Pauls E, Clotet B, Esté JA.

AIDS. 2008 Jan 2;22(1):23-31.


Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.

Jiang X, Feyertag F, Meehan CJ, McCormack GP, Travers SA, Craig C, Westby M, Lewis M, Robertson DL.

J Virol. 2015 Nov;89(22):11457-72. doi: 10.1128/JVI.01384-15. Epub 2015 Sep 2.


Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism.

Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, Sandres-Sauné K, Cuzin L, Marchou B, Massip P, Izopet J.

AIDS. 2008 Sep 12;22(14):F11-6. doi: 10.1097/QAD.0b013e32830ebcd4.


HIV-1 tropism determination using a phenotypic Env recombinant viral assay highlights overestimation of CXCR4-usage by genotypic prediction algorithms for CRF01_AE and CRF02_AG [corrected].

Mulinge M, Lemaire M, Servais JY, Rybicki A, Struck D, da Silva ES, Verhofstede C, Lie Y, Seguin-Devaux C, Schmit JC, Bercoff DP.

PLoS One. 2013 May 8;8(5):e60566. doi: 10.1371/journal.pone.0060566. Print 2013. Erratum in: PLoS One. 2013;8(7). doi:10.1371/annotation/7c0b830d-e75d-4128-ab54-7d5ecfd99d19.


Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage.

Sander O, Sing T, Sommer I, Low AJ, Cheung PK, Harrigan PR, Lengauer T, Domingues FS.

PLoS Comput Biol. 2007 Mar 30;3(3):e58. Epub 2007 Feb 8.


Characterization of HIV-1 entry inhibitors with broad activity against R5 and X4 viral strains.

Sironi F, Malnati M, Mongelli N, Cozzi P, Guzzo C, Ghezzi S, Martínez-Romero C, García-Sastre A, Lusso P, Jabes D, Biswas P.

J Transl Med. 2015 Apr 2;13:107. doi: 10.1186/s12967-015-0461-9.


[Mechanisms of resistance and failure of treatment with maraviroc].

Delgado R.

Enferm Infecc Microbiol Clin. 2008 Oct;26 Suppl 11:28-33. Review. Spanish.


Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.

Lin G, Bertolotti-Ciarlet A, Haggarty B, Romano J, Nolan KM, Leslie GJ, Jordan AP, Huang CC, Kwong PD, Doms RW, Hoxie JA.

J Virol. 2007 Sep;81(18):9956-66. Epub 2007 Jul 3.


Prediction of HIV-1 coreceptor usage (tropism) by sequence analysis using a genotypic approach.

Sierra S, Kaiser R, Lübke N, Thielen A, Schuelter E, Heger E, Däumer M, Reuter S, Esser S, Fätkenheuer G, Pfister H, Oette M, Lengauer T.

J Vis Exp. 2011 Dec 1;(58). pii: 3264. doi: 10.3791/3264.


Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage.

Svicher V, Alteri C, Artese A, Zhang JM, Costa G, Mercurio F, D'Arrigo R, Alcaro S, Palù G, Clementi M, Zazzi M, Andreoni M, Antinori A, Lazzarin A, Ceccherini-Silberstein F, Perno CF; OSCAR study group.

Antivir Ther. 2011;16(7):1035-45. doi: 10.3851/IMP1862.


Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry.

Li Y, Yang D, Wang JY, Yao Y, Zhang WZ, Wang LJ, Cheng DC, Yang FK, Zhang FM, Zhuang M, Ling H.

PLoS One. 2014 Jan 21;9(1):e86083. doi: 10.1371/journal.pone.0086083. eCollection 2014.

Supplemental Content

Support Center